{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:06Z","timestamp":1791834966368,"version":"4.3.4"},"reference-count":38,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Royal Adelaide Hospital A. R. Clarkson Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>There are growing reports of dopamine agonist (DA)-induced impulse control disorders (ICDs) in hyperprolactinemic patients. However, the magnitude of this risk and predictive factors remain uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine ICD prevalence and risk factors in DA-treated hyperprolactinemic patients compared to community controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, Setting and Participants<\/jats:title>\n                  <jats:p>Multicenter cross-sectional analysis of 113 patients and 99 healthy controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Participants completed a neuropsychological questionnaire consisting of the Depression Anxiety Stress Scale (DASS21), Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease (QUIP-S), Hypersexual Behavior Inventory (HBI), Hypersexual Behavior Consequences Scale and Social Desirability Response Set Scale. Demographic and clinical data were collated to determine ICD risk factors. Patients testing positive for an ICD were offered a semistructured psychological interview.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients were more likely than controls to test positive by QUIP-S for any ICD (61.1 vs 42.4%, P = .01), hypersexuality (22.1 vs 8.1%, P = .009), compulsive buying (15.9 vs 6.1%, P = .041) and punding (18.6 vs 6.1%, P = 0.012), and by HBI for hypersexuality (8.0 vs 0.0%, P = 0.004). Independent risk factors were male sex (odds ratio [OR] 13.85), eugonadism (OR 7.85), Hardy\u2019s tumor score and psychiatric comorbidity (OR 6.86) for hypersexuality, and age (OR 0.95) for compulsive buying. DASS21 subset scores were higher in patients vs controls and in patients with vs without different ICDs. Only 19\/51 (37.3%) interviewed patients were aware of the relationship between DAs and ICDs before the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DA therapy poses a high, previously underestimated risk of ICDs, especially in the form of hypersexuality in eugonadal men.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz076","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T15:12:20Z","timestamp":1570115540000},"page":"e108-e118","source":"Crossref","is-referenced-by-count":78,"title":["Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6482","authenticated-orcid":false,"given":"Sunita M C","family":"De Sousa","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia"},{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia alliance, Adelaide, Australia"},{"name":"Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Baranoff","sequence":"additional","affiliation":[{"name":"Centre for Treatment of Anxiety and Depression, Mental Health Directorate, Central Adelaide Local Health Network, Adelaide, Australia"},{"name":"School of Psychology, University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Louise","family":"Rushworth","sequence":"additional","affiliation":[{"name":"School of Medicine, Sydney, University of Notre Dame, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Butler","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Sorbello","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Vorster","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Thompson","sequence":"additional","affiliation":[{"name":"Hormones and Cancer, Garvan Institute of Medical Research, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann I","family":"McCormack","sequence":"additional","affiliation":[{"name":"Hormones and Cancer, Garvan Institute of Medical Research, Sydney, Australia"},{"name":"St Vincent\u2019s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warrick J","family":"Inder","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia"},{"name":"Princess Alexandra-Southside Clinical Unit, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Torpy","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"issue":"12","key":"2021122017425313100_CIT0001","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122017425313100_CIT0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2021122017425313100_CIT0003","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1530\/EJE-18-0667","article-title":"Management of endocrine disease: impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?","volume":"179","author":"Barake","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2021122017425313100_CIT0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2021122017425313100_CIT0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021122017425313100_CIT0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","article-title":"Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment","volume":"167","author":"Elenkova","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"12","key":"2021122017425313100_CIT0007","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med."},{"issue":"2","key":"2021122017425313100_CIT0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2021122017425313100_CIT0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122017425313100_CIT0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","article-title":"Pathological gambling and hypersexuality in cabergoline-treated prolactinoma","volume":"190","author":"Falhammar","year":"2009","journal-title":"Med J Aust."},{"issue":"6","key":"2021122017425313100_CIT0011","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13339","article-title":"Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma","volume":"86","author":"Bulwer","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2021122017425313100_CIT0012","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1530\/EC-18-0030","article-title":"Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist","volume":"7","author":"Athanasoulia-Kaspar","year":"2018","journal-title":"Endocr Connect."},{"issue":"8","key":"2021122017425313100_CIT0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281580","article-title":"Pathological gambling induced by dopamine agonists","volume":"79","author":"Gahr","year":"2011","journal-title":"Fortschr Neurol Psychiatr."},{"issue":"5","key":"2021122017425313100_CIT0014","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","article-title":"Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma","volume":"36","author":"Thondam","year":"2013","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"2021122017425313100_CIT0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7861\/clinmedicine.14-2-205","article-title":"Lesson of the month (1): cabergoline\u2014\u201ci eat funny on that.\u201d","volume":"14","author":"Premaratne","year":"2014","journal-title":"Clin Med (Lond)."},{"issue":"2","key":"2021122017425313100_CIT0016","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine."},{"issue":"5","key":"2021122017425313100_CIT0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol."},{"issue":"6","key":"2021122017425313100_CIT0018","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122017425313100_CIT0019","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine."},{"issue":"7","key":"2021122017425313100_CIT0020","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122017425313100_CIT0021","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","edition":"4"},{"key":"2021122017425313100_CIT0022","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","edition":"5th ed"},{"issue":"10","key":"2021122017425313100_CIT0023","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord."},{"issue":"5","key":"2021122017425313100_CIT0024","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"2021122017425313100_CIT0025","volume-title":"Manual for the Depression Anxiety Stress Scales.","author":"Lovibond","edition":"2nd ed"},{"key":"2021122017425313100_CIT0026","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1037\/1040-3590.10.2.176","article-title":"Psychometric properties of the 42-item and 21-item versions of the depression anxiety stress scales in clinical groups and a community sample","volume":"10","author":"Antony","year":"1998","journal-title":"Psychol Assessment."},{"issue":"Pt 2","key":"2021122017425313100_CIT0027","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1348\/014466505X29657","article-title":"The short-form version of the depression anxiety stress scales (DASS-21): construct validity and normative data in a large non-clinical sample","volume":"44","author":"Henry","year":"2005","journal-title":"Br J Clin Psychol."},{"key":"2021122017425313100_CIT0028","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/10720162.2011.555709","article-title":"Reliability, validity, and psychometric development of the hypersexual behavior inventory in an outpatient sample of men","volume":"18","author":"Reid","year":"2011","journal-title":"Sex Addict Compulsivity."},{"issue":"3","key":"2021122017425313100_CIT0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1556\/JBA.1.2012.001","article-title":"Psychometric development of the hypersexual behavior consequences scale","volume":"1","author":"Reid","year":"2012","journal-title":"J Behav Addict."},{"key":"2021122017425313100_CIT0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/001316448904900315","article-title":"A five-item measure of socially desirable response set","volume":"49","author":"Hays","year":"1989","journal-title":"Educ Psychol Measur."},{"issue":"3","key":"2021122017425313100_CIT0031","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","article-title":"Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls","volume":"96","author":"Athanasoulia","year":"2012","journal-title":"Neuroendocrinology."},{"issue":"2","key":"2021122017425313100_CIT0032","doi-asserted-by":"crossref","first-page":"T101","DOI":"10.1530\/JOE-15-0213","article-title":"60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-prolactin axis","volume":"226","author":"Grattan","year":"2015","journal-title":"J Endocrinol."},{"issue":"2","key":"2021122017425313100_CIT0033","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary."},{"issue":"1","key":"2021122017425313100_CIT0034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."},{"issue":"5","key":"2021122017425313100_CIT0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol."},{"issue":"3","key":"2021122017425313100_CIT0036","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12020-017-1247-z","article-title":"Hypersexuality in men with prolactinomas treated with dopamine agonists","volume":"56","author":"Bancos","year":"2017","journal-title":"Endocrine."},{"issue":"7","key":"2021122017425313100_CIT0037","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.parkreldis.2013.03.004","article-title":"Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson\u2019s disease","volume":"19","author":"Valen\u00e7a","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"2021122017425313100_CIT0038","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/ejn.14177","article-title":"Pharmacological insights into impulsive-compulsive spectrum disorders associated with dopaminergic therapy","volume":"50","author":"Napier","year":"2019","journal-title":"Eur J Neurosci."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz076\/30097975\/dgz076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e108\/41823974\/dgz076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e108\/41823974\/dgz076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T17:43:46Z","timestamp":1640022226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/e108\/5580592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,3]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz076","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,10,3]]}}}